Menu
Back to Journals » OncoTargets and Therapy » Volume 5
Emerging treatment options for patients with recurrent advanced thymic epithelial tumors
Authors Evans T
Received 17 April 2012
Accepted for publication 20 June 2012
Published 7 September 2012 Volume 2012:5 Pages 177—184
DOI https://doi.org/10.2147/OTT.S23267
Review by Single anonymous peer review
Peer reviewer comments 2
Tracey L Evans
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
Abstract: The purpose of this review article is to review recent advances in the treatment of advanced thymic epithelial tumors. These tumors are generally responsive to cytotoxic combination chemotherapy in the first-line setting. While newer agents have shown efficacy in the salvage setting, there is no one standard approach. A multitude of targeted agents have shown promise generally in case reports, though as of yet, nothing has shown consistent benefit. Because of the rarity of thymic epithelial tumors, clinical trial enrollment is difficult but nevertheless essential.
Keywords: thymoma, thymic carcinoma, targeted therapy, epidermal growth factor receptor
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.